Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Piperazin-1-Yl-Pyrimidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.51 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL101561 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL6861317 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL169214 | 0.98 | ALDH1A1 (0.95) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL893739 | 0.98 | ALDH1A1 (0.95) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL27920766 | 0.95 | ALDH1A1 (0.91) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL5375472 | 0.95 | ALDH1A1 (0.91) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL27324991 | 0.95 | ALDH1A1 (0.91) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL27146448 | 0.92 | ALDH1A1 (0.85) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| SCHEMBL1254909 | 0.90 | ALDH1A1 (0.81) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| 2-Piperazin-1-Yl-Pyrimidine SCHEMBL28926339 | 0.86 | KDM4E (0.75) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108178759-B | Synthesis method of α -adrenoceptor antagonist | 上海瑞纷医药科技有限责任公司 | 2020-06-09 | — | — | CN | claimed |
| CN-108440505-A | The total synthesis method of eptapirone | 中南大学 | 2018-08-24 | — | — | CN | claimed |
| CN-104803923-B | A kind of preparation method of 1 (2 pyrimidine) piperazine hydrochloride | 江苏恩华药业股份有限公司 | 2017-09-05 | — | — | CN | claimed |
| CN-104803923-A | Preparation method of 1-(2-pyrimidine) piperazine hydrochloride | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2015-07-29 | — | — | CN | claimed |
| CN-102180867-B | Synthesis method of N-{2-[4-(2-pyrimidyl)-1-piperazine}adamantine-1-formide | UNIV GUANGDONG TECHNOLOGY | 2013-01-09 | — | — | CN | claimed |
| CN-102180867-A | Synthesis method of N-{2-[4-(2-pyrimidyl)-1-piperazine}adamantine-1-formide | UNIV GUANGDONG TECHNOLOGY | 2011-09-14 | — | — | CN | claimed |
| CN-101318935-B | Method for preparing hydrochloric 1-(2-pyrimidine) diethylenediamine compound | NANTONG KANGXING PHARMACEUTICAL CO LTD | 2010-11-10 | — | — | CN | claimed |
| CN-101318935-A | Method for preparing hydrochloric 1-(2-pyrimidine) diethylenediamine compound | NANTONG KANGXING PHARMACEUTICA (CN) | 2008-12-10 | — | — | CN | claimed |
| CN-119409681-A | Preparation method of buspirone hydrochloride | 北京华素制药股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| CN-119019331-A | Tricyclic derivative and application thereof | 江苏恩华药业股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-0151140-B1 | 2-PIPERAZINOPYRIMIDINE SALT, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | SANOFI (FR) | 1986-12-03 | — | — | EP | disclosed |
| US-4602015-A | 2-piperazinopyrimidine salt and pharmaceutical compositions containing it | SANOFI (FR) | 1986-07-22 | — | — | US | disclosed |
| EP-0151140-A1 | 2-PIPERAZINOPYRIMIDINE SALT, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT. | SANOFI SA (FR) | 1985-08-14 | — | — | EP | disclosed |
| WO-1985000168-A1 | 2-PIPERAZINOPYRIMIDINE SALT, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | SANOFI (FR) | 1985-01-17 | — | — | WO | disclosed |
| EP-0115714-A1 | Pharmaceutical composition with psychotropic dopaminergic action | SANOFI S.A. (FR) | 1984-08-15 | — | — | EP | disclosed |
| EP-0109340-A2 | Acid salts of 2-piperazinopyrimidine, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | ADRB1 290/4885HRH1 30/4885HTR2A 4183/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | ADRB1 2834/4885HRH1 3648/4885HTR2A 2904/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | ADRB1 728/4885HRH1 49/4885HTR2A 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.